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Abstract
Background: This short communication focuses the on articular cartilage and the subchondral bone, both of
which play important roles in the development of osteoarthritis (OA). There are indications that estrogen-
deficiency, as the post-menopausal state, accelerate the development of OA.
Findings: We investigated, which extracellular matrix (ECM) protein, proteases and different pro-inflammatory
factors was up- or down-regulated in the knee joint tissue in response to estrogen-deficiency in rats induced by
ovariectomy. These data support previous findings that several metalloproteinases (MMPs) and cysteine proteases
are co-regulated with numerous collagens and proteoglycans that are important for cartilage integrity. Furthermore
quite a few pro-inflammatory cytokines were regulated by estrogen deprivation.
Conclusion: We found multiple genes where regulated in the joint by estrogen-deficiency, many of which
correspond well with our current knowledge of the pathogenesis of OA. It supports that estrogen-deficiency (e.g.
OVX) may accelerate joint deterioration. However, there are also data that draw attention the need for better
understanding of the synergy between proteases and tissue turnover.
Introduction
Post-menopausal women have a higher incident rate of
o s t e o a r t h r i t i s( O A )a n do s t e o p o r o s i s( O P )t h a nt h a to f
age-matched men [1,2]. There are indications that peri-
menopausal women receiving estrogen replacement
therapy (ERT) had lower risk of developing radiographic
knee and hip OA and that the protective effect was
increased with increased duration of ERT treatment [1].
This is in line with findings that also bone turnover is
increased due to estrogen-deficiency [3]. Mouritzen et
al. (2005) found that urinary levels of cartilage and bone
turnover markers (i.e. C-terminal telopeptide of type I
and II collagen, CTX-I/II) were increased in post-meno-
pausal women compared to pre-menopausal women.
Since then it has been shown that selective estrogen-
receptor modulators (SERMs) given to postmenopausal
women decrease the level of CTX-II about 50% of base-
line (12-month follow-up). These markers are generated
by enzymatic processing of type II and I collagen,
respectively, which is a result of induced cellular
responses. Furthermore, it has been shown that adult
articular cartilage expresses estrogen receptors and these
can be activated and thereby induce production of
extracellular matrix (ECM) molecules (e.g. proteoglycans
and collagens) [4]. Ovariectomy of rats led to similar
results; estrogen-deficiency led to cartilage damage and
increased bone resorption, which could be prevented by
administrations of estrogen [5
-7]. Comparable studies
have been done in other species [8]. We investigated
which genes related to cartilage turnover and integrity
was regulated in response to estrogen deprivation by
comparing the mRNA expression between sham and
ovariectomized rats.
Methods
Six month old female rats were either ovariectomized
( O V X ,n=5 )o rs h a mo p e r a t e d( n=5 ) .A f t e rr e c o v e r y
the rats were house under standard conditions for 8
weeks, and terminated. All animal experiments were
approved by the local ethical authorities ("Dyreforsøg-
stilsynet”, approval no. DK-2006/561-1239). The knees
were isolated right after termination and the cartilage
and subchondral compartment was detached from the
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RNA was isolated from the pulverized tissue using stan-
dard phenol based extraction method. The mRNA was
hybridized to an Affymetrix GeneChip [9].
Expression data was retrieved from the internal micro-
array database discriminating 1.5-fold and 2-fold signifi-
cant (p < 0.05 by Student’s t-test) increased or
decreased expression of individual genes when compar-
ing the OVX and sham group, which gave a list of 2.959
and 579 genes, respectively. An objective search where
made on database terms: Extracellular matrix protein,
Protease/Proteinase, Cytokine, Growth factor, Bone and
Cartilage. From these searched, literature based and sub-
jectively guided sorting was done on structural proteins
involved in cartilage and bone tissue remodeling and
destruction, as well as cartilage and bone related factors.
Each of the genes in question was reviewed by searches
(term: “gene name” cartilage and/or bone) on Pubmed
http://www.ncbi.nlm.nih.gov/pubmed/, IHOP http://
www.ihop-net.org/UniPub/iHOP/, Rat genome database
http://rgd.mcw.edu/tools/genes/ and HUGO gene
nomenclature Committee http://www.genenames.org/.
Expression of ECM proteins in response to estrogen
deficiency
A total of nine relevant ECM proteins genes were found
to be differentially expressed in the OVX group com-
p a r e dt ot h es h a mg r o u p( F i g u r e2 A ) .O n l yo n eE C M
gene were significantly up-regulated; Dentin matrix pro-
tein 1 (DMP1). DMP1 is expressed in mineralized tis-
sues such as hypertrophic cartilage and bone, where it
can bind Ca
2+ and regulate matrix mineralization [10].
There were eight ECM genes down-regulated. Fibromo-
dulin (FMOD) is known to interact with both type I and
II collagen in bone and cartilage, respectively [11].
Through its binding of collagens it aids stabilization of
the tissue. Several collagens (Col) were down-regulated;
type IVa2, VIa2, IXa and XV. Type VI and IX are some
of the minor collagens of the mature cartilage that are
known to interact with other matrix components, such
as hyaluronan, heperan sulfate and Chondroitin sulfate
proteoglycans. Type XV collagen is member of the
FACIT collagen family (fibril-associated collagens with
interrupted helices) and mainly expressed by fibroblastic
Figure 1 The tibia plateau was separated from the tibia by a
cut (broken line) in the upper half of the secondary
ossification site (white area). The light gray of the cut-off piece
depicts the subchondral bone and the dark grey the articular
cartilage. Total RNA was extracted from this piece.
Figure 2 Comparison between the expression levels of
selective genes in the tibia plateau of OVX rats and sham rats
(indicated as fold expression of sham). A) The fold expression of
ECM proteins; B) The fold expression of ECM proteases and; and, C)
The fold expression of growth factors and cytokines involved in
cartilage and bone turnover. Dotted line indicates a 1.5-fold
expression level compared to sham. P < 0.05 were for all.
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lamina and widely distributed throughout the body, like
many other collagens it is involved in tissue stabilization
and flexibility [12]. Two chondroitin sulfate proglycans
were also down-regulated in the joint tissue of OVX
rats: CSPG2 (Versican) and 4 (NG2) (Figure 2A). Both
have been shown to be involved in the regulations of
bone development, chondrogenesis and angiogenesis,
but only present in low amounts in mature cartilage and
bone [13]. Laminin alpha 5 (LAMa5), a subunit of lami-
nin 5, which is observed in the basement membrane. It
has been shown to promote bone growth and regenera-
tion through cell adhesion and motility [14].
Expression of ECM degrading proteases in response to
estrogen deficiency
Eight ECM degrading proteases were up-regulated in the
joints of the OVX rats (Figure 2B). Metalloproteinase
(MMP) 8 (collagenase-2), 9 (gelatinase B), 11 (stromely-
sin-3) and 16 (MT3-MMP) are collagen and proteogly-
can degrading protease, which have been implicated as
drivers of joint degradation [15]. Cathepsins (Cat) C, Z,
K and H, which are all cysteine proteases, have been
shown to play vital role the regulation of tissue turn-
over. CatC is a dipeptidyl aminopeptidase, which is
involved in the activation of serine proteases such as
CatG and elastase [16]. CatZ is also a dipeptidyl pepti-
dase, but its function in cartilage and bone turnover is
unclear. CatK is mainly expressed by osteoclast and are
responsible for the release of the bone turnover marker
CTX-I. It has been found to be elevated in OVX animals
and post-menopausal women. CatH cleaves osteocalcin
in bone and might therefore be an important protease
in bone turnover [17]. The A Disintegrin And Metallo-
peptidase 10 (ADAM10) is expressed by chondrocyte in
bone development and in OA chondrocytes. It is there-
fore believed to be involved in the remodeling of carti-
lage [18].
Six proteases were down-regulated; MMP3 and the
aggrecanases ADAMTS-like 4, ADAM15 and
ADAMTS5, as well as bone morphogenic protein (BMP)
1 and tissue inhibitor metalloproteinase 3 (TIMP3) (Fig-
ure 2B). MMP3 can degrade fibrillar collagens such as
type II and I collagen [19]. MMP3 has been shown to
be elevated in inflammatory diseases, such as rheuma-
toid arthritis; however it is mainly expressed by the con-
nective tissue like the synovial membrane and to a
lesser degree by bone and cartilage. ADAM15 has been
shown to cleave ECM components such as gelatin and
type IV collagen. It is has been found to be upregrulated
in OA chondrocytes [20]. ADAMTS-like 4 and
ADAMTS5 (ADAM with thrombin mortif) are known
for their capability to degrade proteoglycans such as
aggrecan and versican [21]. It intriguing that ADAMTS5
is down-regulated, since previous studies have indicated
it to be a primary protease in OA cartilage degradation
[22]. In contrast, others have shown ADAMTS’ are
involved in both degradation and remodeling of the tis-
sue [23,24]. The endogenous MMP and aggrecanase
inhibitor TIMP3 was also down-regulated. TIMP3 is
believed to be an important regulator of cartilage and
bone turnover, through its inhibition of MMPs and
aggrecanases [21]. In contrast to other BMPs, BMP1
does not belong to the TGF-b family of proteins. It is a
metalloproteinase that acts on procollagen I, II, and III
and has been implicated in cartilage development [25].
Expression of cytokines and growth factors in response
to estrogen deficiency
Next we searched for factors directly involved in bone
and/or cartilage regulation.W ef o u n dt h a tf i v eg e n e s
were significantly up-regulated and 11 were significantly
down-regulated in the OVX animals (Figure 2C). Scler-
ostin (SOST) was markedly over-expressed in the OVX
rats. It is expressed by osteoclast and is a negative regu-
lator of bone formation through activation of the Wnt
pathway [26]. BMP2 through BMP7 belong to the trans-
forming growth factor beta superfamily of proteins.
Whereas BMP6, -5 and -2 were down-regulated, BMP3
was up-regulated. BMP3 is known to induce bone for-
mation and cartilage development and to have antago-
nistic effect on other BMPs [27]. Transforming growth
factors beta-2 (TGFb2) expression was also elevated.
TGFb2 is a multi-factorial regulator of cellular growth
in developing systems and in repair of adult bone and
cartilage [28]. TNFsf11, also known as RANKL, is a nat-
ural and necessary surface-bound molecule that activates
osteoclasts, cells involved in bone resorption. Overpro-
duction of RANKL is implicated in a variety of degen-
erative bone diseases, such as arthritis [29]. Osteoclast
stimulating factor 1 (OSTF1) expression was also
increased in the OVX rats’ joints (Figure 2C). It is
known to increase osteoclast formation and bone
resorption through signal transduction, however only lit-
tle is known about the family member of osteoblast sti-
mulation factors [30]. Insulin-like growth factor 2
(IGF2), IGF binding protein 2 (IGFBP) and IGFBP6
were all down-regulated in the OVX rats. IGF2 is
k n o w nt ob i n db o t ht oI G F B P 2a n dI G F B P 6 ,a n di t s
effect on bone cells is thereby prevented (e.g. osteoblast
proliferation) [31]. Connective tissue growth factor
(CTGF) is a potent stimulator for proliferation and dif-
ferentiation of osteoblast and chondrocytes through reg-
ulation of cellular associated genes [32]. The tightly
related proteins Fibroblast growth factor receptor 3
(FGFR3) and the parathyroid hormone-like hormone
(PTHLH), which were both down-regulated, play central
roles in the physiological regulation of bone formation,
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and probably plays a role in the physiological regulation
of bone resorption, by enhancing osteoclast formation.
Signaling by FGFR3 and PTHLH coordinates cartilage
and bone development. PTHLH is also an essential phy-
siological regulator of adult bone mass [33]. The calci-
tropic hormone Stanniocalcin 1 (STC1) was down-
regulated in the OVX rats. It is involved in the regula-
tion of longitudinal bone growth [34]. Nitric oxide
synthase 3 (NOS3, eNOS) was also down-regulated. It
has been shown that estrogen induces NOS3 expression
in endothelial cells and osteoblasts, raising the possibi-
lity that NO derived from the NOS3 pathway plays a
role in mediating the effects of sex hormones on bone
[35]. BMP2, -5 and -6, which were down-regulated in
the OVX rats (Figure 2C), all induces cartilage and bone
formation and play role in joint integrity [27].
Discussion and Conclusion
We were interested in investigating the effect of ovar-
iectomy (i.e. estrogen deficiency) on the joint. Here we
use a rodent model that in previous study has been
shown to develop bone and cartilage changes, resem-
bling pathological features of OA. We have made a
guided search on ECM molecules, matrix proteases and
cytokines/growth factors that have previously been
directly implicated in bone and cartilage turnover.
Although the search was made electronically, it is still
somewhat subjective, because the database keywords
may not be ubiquitous and fulfilling. Nevertheless we
found several differentially express genes, which are
known to play a role in development of joint degenera-
tive disease such as OA.
Animal studies have shown that by inhibiting osteo-
clast activity, the histo-pathological score (cf. Mankin)
could be markedly reduced, suggesting that osteoclasts
play a central role in OA and cartilage breakdown. Also
bone formation cells, osteoblast, seem to play an impor-
tant role in OA: osteoblasts isolated from subchondral
bone of OA hips demonstrate an altered and more
active phenotype. Furthermore, IGF-1 (a bone promot-
ing factor as well as several growth factors (e.g. BMPs,
TGF and FGF) has been shown to be elevated in OA-
subchondral explant cultures.
In conclusion, we found that extracellular matrix pro-
teins, proteases and paracrine factors known to be
involved in joint degenerative diseases were either
down- or up-regulated in response to estrogen-deple-
tion. As a whole, the data support current knowledge;
however there are some discrepancies, which stresses
that more investigation is needed to fully understand
the pathogenesis of post-menopausal OA.
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